These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37160252)

  • 41. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996).
    George B; Harris A; Mitchell A
    Pharmacoeconomics; 2001; 19(11):1103-9. PubMed ID: 11735677
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-utility analysis of orthoptic screening in kindergarten: a Markov model based on data from Germany.
    König HH; Barry JC
    Pediatrics; 2004 Feb; 113(2):e95-108. PubMed ID: 14754978
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Generalisability in economic evaluation studies in healthcare: a review and case studies.
    Sculpher MJ; Pang FS; Manca A; Drummond MF; Golder S; Urdahl H; Davies LM; Eastwood A
    Health Technol Assess; 2004 Dec; 8(49):iii-iv, 1-192. PubMed ID: 15544708
    [TBL] [Abstract][Full Text] [Related]  

  • 44. QALYs: are they helpful to decision makers?
    McGregor M; Caro JJ
    Pharmacoeconomics; 2006; 24(10):947-52. PubMed ID: 17002477
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment.
    Zubek VB; Konski A
    Mol Diagn Ther; 2009; 13(1):31-47. PubMed ID: 19351214
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of a Stratified National Breast Screening Program in the United Kingdom: An Early Model-Based Cost-Effectiveness Analysis.
    Gray E; Donten A; Karssemeijer N; van Gils C; Evans DG; Astley S; Payne K
    Value Health; 2017 Sep; 20(8):1100-1109. PubMed ID: 28964442
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advantages and limitations of utility assessment methods in rheumatoid arthritis.
    Beresniak A; Russell AS; Haraoui B; Bessette L; Bombardier C; Duru G
    J Rheumatol; 2007 Nov; 34(11):2193-200. PubMed ID: 17937471
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incorporating Portfolio Uncertainty in Decision Rules for Healthcare Resource Allocation.
    Sendi P; Gafni A; Birch S; Walter SD
    Healthcare (Basel); 2021 Mar; 9(3):. PubMed ID: 33799361
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A cost-utility analysis of sacral anterior root stimulation (SARS) compared with medical treatment in patients with complete spinal cord injury with a neurogenic bladder.
    Morlière C; Verpillot E; Donon L; Salmi LR; Joseph PA; Vignes JR; Bénard A
    Spine J; 2015 Dec; 15(12):2472-83. PubMed ID: 26291400
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Moving Beyond Quality-Adjusted Life-Years in Elderly Care: How Can Multicriteria Decision Analysis Complement Cost-Effectiveness Analysis in Local-Level Decision Making.
    Hoedemakers M; Tsiachristas A; Rutten-van Mölken M
    Value Health; 2022 Oct; 25(10):1717-1725. PubMed ID: 35623974
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
    Phisalprapa P; Supakankunti S; Chaiyakunapruk N
    J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
    [No Abstract]   [Full Text] [Related]  

  • 52. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers.
    Meunier A; Longworth L; Gomes M; Ramagopalan S; Garrison LP; Popat S
    Pharmacoeconomics; 2023 Aug; 41(8):1011-1025. PubMed ID: 37296369
    [TBL] [Abstract][Full Text] [Related]  

  • 54. iStent for Adults With Glaucoma: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(10):1-42. PubMed ID: 34422143
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
    Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation.
    Rodgers M; McKenna C; Palmer S; Chambers D; Van Hout S; Golder S; Pepper C; Todd D; Woolacott N
    Health Technol Assess; 2008 Nov; 12(34):iii-iv, xi-xiii, 1-198. PubMed ID: 19036232
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Eliciting stated preferences for health-technology adoption criteria using paired comparisons and recommendation judgments.
    Johnson FR; Backhouse M
    Value Health; 2006; 9(5):303-11. PubMed ID: 16961548
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Severity-Adjusted Probability of Being Cost Effective.
    Versteegh MM; Ramos IC; Buyukkaramikli NC; Ansaripour A; Reckers-Droog VT; Brouwer WBF
    Pharmacoeconomics; 2019 Sep; 37(9):1155-1163. PubMed ID: 31134467
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incorporating risk attitude into Markov-process decision models: importance for individual decision making.
    Cher DJ; Miyamoto J; Lenert LA
    Med Decis Making; 1997; 17(3):340-50. PubMed ID: 9219195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.